孙佳,李容,勾健,潘文琪,陆苑,刘春花,黄勇,刘亭
SUN Jia,LI Rong,GOU Jian,PAN Wenqi,LU Yuan,LIU Chunhua,HUANG Yong,LIU Ting

• 1:贵州医科大学贵州省药物制剂重点实验室
• 2:贵州医科大学药学院
• 3:贵州医科大学临床医学院
• 4:贵州医科大学民族药与中药开发应用教育部工程研究中心&省部共建药用植物功效与利用国家重点实验室

摘要(Abstract)：

目的 研究丹参-川芎嗪配伍前后对急性心肌缺血(AMI)大鼠体内排泄及Ⅱ相代谢酶的影响。方法 通过大鼠皮下注射盐酸异丙肾上腺素复制AMI模型，尾静脉注射参芎葡萄糖注射液(SGI组)、丹参注射液(DGI组)以及川芎嗪注射液(LGI组)后，收集不同时间段的尿液、粪便，UPLC-MS/MS法测定丹参素、川芎嗪的含量；Western blot检测各组大鼠肝脏中尿苷二磷酸葡萄糖醛酸转移酶1A1(UGT1A1)和尿苷二磷酸葡萄糖醛酸转移酶1A6(UGT1A6)酶的表达情况。结果 丹参素主要经尿液排泄，在尿液中的累积排泄率为31.35%～33.27%,在粪便中的累计排泄率为4.52%～6.08%;川芎嗪在尿液、粪便中的累积排泄率较低，均不足1%;与DGI组相比，SGI组中UGT1A1和UGT1A6的表达增加(P<0.05,P<0.01);与LGI组相比，SGI组中UGT1A6的表达显著增加(P<0.001)。结论 配伍后介导川芎嗪Ⅱ相代谢的UGT1A1和UGT1A6酶表达升高，使川芎嗪的原型排泄量降低。
Objective To investigate the effect of Salvia miltiorrhiza and ligustrazine before and after compatibility on the excretions in rats with acute myocardial ischemia(AMI). Methods AMI model was established by subcutaneous injection of isoproterenol hydrochloride. Urine and feces were collected at different time periods after rat tail vain injection of Shenxiong glucose injection(SGI group), Danshen glucose injection(DGI group) and Ligustrazine Phosphate Injection(LGI group). UPLC-MS/MS were applied to measure the contents of Salvianic acid A and ligustrazine. Western blot was used to detect the expressions of rat liver uridine diphosphate glucuronosyltransferase 1A1(UGT1A1) and UGT1A1A6 in each group. Results Salvianic acid A was mainly excreted through urine with the cumulative excretion rate ranging from 31.35% to 33.27%, and the cumulative excretion rate in feces ranging from 4.52% to 6.08%. The cumulative excretion rates of ligustrazine in urine and feces were less than 1%. The expression levels of UGT1A1 and UGT1A6 in SGI group were significantly increased when compared to DGI group(P<0.05 and P<0.01, respectively). When compared to LGI group, the UGT1A6 expression in SGI group was significantly elevated(P<0.001). Conclusion The expressions of UGT1A1 and UGT1A6 which mediate the phase Ⅱ metabolism of ligustrazine are increased after compatibility, leading to a decrease of prototype excretion amount of ligustrazine.

关键词(KeyWords)： 参芎葡萄糖注射液;配伍;急性心肌缺血;排泄;差异;Ⅱ相代谢酶
shenxiong glucose injection;compatibility;acute myocardial ischemia;excretion;difference;phaseⅡmetabolizing enzyme

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目(81803827);; 贵州省优秀青年科技人才项目(黔科合平台人才[2021]5619);; 贵州省普通高等学校科技拔尖人才项目(黔教合KY字[2021]033);; 大学生创新创业训练计划项目(S202110660059)

作者(Author): 孙佳,李容,勾健,潘文琪,陆苑,刘春花,黄勇,刘亭
SUN Jia,LI Rong,GOU Jian,PAN Wenqi,LU Yuan,LIU Chunhua,HUANG Yong,LIU Ting

DOI: 10.19367/j.cnki.2096-8388.2023.11.006

参考文献(References)：

• [1] LI Z W,HOU J J,DENG Y P,et al.Exploring the protective effects of Danqi Tongmai Tablet on acute myocardial ischemia rats by comprehensive metabolomics profiling[J].Phytomedicine:International Journal of Phytotherapy and Phytopharmacology,2020,74:152918.
• [2] 屈新亮，段广靖，赵博，等.附子-干姜对大鼠急性心肌缺血的抗炎、抗氧化、抗凋亡保护作用及机制研究[J].中药药理与临床，2022,38(3):31-37.
• [3] TANG C L,HU Y D,GAO J,et al.Dexmedetomidine pretreatment attenuates myocardial ischemia reperfusion induced acute kidney injury and endoplasmic reticulum stress in human and rat[J].Life Sciences,2020,257:118004.
• [4] 国家药典委员会.WS-10001(HD-1136)-2002卫生部药品标准第十二册[S].北京：化学工业出版社，2002:118.
• [5] 陆定艳，吴忠秀，孙佳，等.基于蛋白质组学分析参芎葡萄糖注射液拮抗H2O2诱导H9c2细胞氧化损伤的作用机制[J].中国实验方剂学杂志，2022,28(1):141-149.
• [6] 李长健，马贤鹏，聂红.基于网络药理学和分子对接探究参芎葡萄糖注射液抗心肌缺血再灌注损伤的作用机制[J].中国中药杂志，2022,47(10):2759-2766.
• [7] LU D Y,SUN J,ZHENG J,et al.Shenxiong glucose injection inhibits H2O2-induced H9c2 cell apoptosis by activating the ERK signaling pathway[J].Biomedicine & Pharmacotherapy,2021,143:112114.
• [8] SUN G J,LI X M,WEI J X,et al.Pharmacodynamic substances in Salvia miltiorrhiza for prevention and treatment of hyperlipidemia and coronary heart disease based on lipidomics technology and network pharmacology analysis[J].Biomedecine & Pharmacotherapie,2021,141:111846.
• [9] WANG K R,HAO Y S,WANG C G,et al.Simultaneous improvement of physical stability,dissolution,bioavailability,and antithrombus efficacy of Aspirin and Ligustrazine through cocrystallization[J].International Journal of Pharmaceutics,2022,616:121541.
• [10]陆兔林，苏联麟，季德，等.CYP450酶与中药代谢相互作用及酶活性测定的研究进展[J].中国中药杂志，2015,40(18):3524-3529.
• [11]张静雅，刘利琴，李容，等.参芎葡萄糖注射液在正常和急性心肌缺血大鼠体内的药动学差异[J].中国药房，2022,33(4):433-438.
• [12]刘林林，李辉，何丹，等.利用RRLC-QqQ-MSn方法分析比较青皮、陈皮提取物在大鼠尿液及粪便中代谢及排泄过程[J].中国中药杂志，2018,43(22):4519-4527.
• [13]孙佳，勾健，刘利琴，等.隔山消提取物在正常和功能性消化不良大鼠尿液、粪便中的排泄研究[J].中国中药杂志，2022,47(23):6355-6364.
• [14]石淑亚，王连生.Ⅱ相代谢及其酶的研究进展[J].中国临床药理学与治疗学，2014,19(1):82-89.
• [15]杨然，马晓慧，郭嘉华，等.药物代谢酶的特性[J].中国新药杂志，2016,25(7):751-759.
• [16]张钰，彭英，王广基，等.疾病状态下Ⅱ相代谢酶表达和活性的研究进展[J].中国临床药理学与治疗学，2020,25(6):686-700.
• [17]孙佳，张静雅，李容，等.川芎嗪-丹参配伍前后对药动学及CYP450酶的影响及其相关性[J].中国中药杂志，2022,47(23):6348-6354.
• [18]孙佳，潘洁，秦兰，等.荭草提取物对异丙肾上腺素诱导大鼠急性心肌缺血的作用及机制[J].贵州医科大学学报，2021,46(3):275-280.
• [19]李志华，颜苗，张毕奎，等.基于药动学的甘草配伍减毒机制研究进展[J].中草药，2015,46(23):3611-3616.
• [20]KIM Y W,KANG H E,LEE M G,et al.Liquiritigenin,a flavonoid aglycone from licorice,has a choleretic effect and the ability to induce hepatic transporters and phase-Ⅱ enzymes[J].American Journal of Physiology Gastrointestinal and Liver Physiology,2009,296(2):G372-G381.
• [21]SHI J X,SUN C P,HUANG H L,et al.β-Glucuronidase- and OATP2B1-mediated drug interaction of scutellarin in Dengzhan Xixin Injection:a formulation aspect[J].Drug Development Research,2020,81(5):609-619.
• [22]刘小娟，王凌，鲁爽.丹参川芎嗪注射液中盐酸川芎嗪的大鼠排泄特征研究[J].中国临床药理学杂志，2014(9):803-806.
• [23]董庆海，刘慧，司雨，等.基于UPLC-Q/TOF-MS技术对丹参川芎嗪注射液在大鼠体内代谢的研究[J].中南药学，2020,18(6):935-941.
• [24]谭妍，庄笑梅，沈国林，等.川芎嗪的肝微粒体代谢动力学及代谢表型研究[J].药学学报，2014,49(3):374-379.
• [25]MEECH R,HU D G,MCKINNON R A,et al.The UDP-glycosyltransferase (UGT) superfamily:new members,new functions,and novel paradigms[J].Physiological Reviews,2019,99(2):1153-1222.
• [26]李雅珍.参麦注射液主要药效成分的体内过程研究[D].杭州：浙江大学，2020.

文章评论(Comment)：